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En bloc pelvic resection for advanced
ovarian cancer preceded by central ligation
of vessels supplying the tumor bed: a




Background: The resection of all visible malignancies increases the likelihood for long-term survival in epithelial
ovarian cancer. The complete extinguishment of pelvic disease is possible using en bloc pelvic resection. The no-touch
isolation technique aims to reduce cancer cells flowing from the primary tumor site to the liver and other organs by
ligating blood and lymphatic vessels first. objectives are to present the operative details and to establish the feasibility of
the modified technique of en bloc pelvic resection, which begins with the central ligation of vessels supplying the tumor
bed.
Methods: Twenty patients with pelvic tumor extensively infiltrating into adjacent pelvic organs were uniformly
operated on. The surgical plan commenced with incisions along the lateral peritoneal reflections immediately
medial to the white line of Toldt followed by a retroperitoneal central ligation of ovarian and mesenteric vessels
and the ovarian lymphovascular flow. Then, the routine steps of en bloc pelvic resection were performed. Data on
treatment were assessed.
Results: In all cases, no gross residual disease was achieved. The median durations of the surgical procedure and the
hospital stay were 320 min (range: 205–430 min) and 12 days (range: 7–44 days), respectively. The complications were as
follows: wound infection (n = 1), anastomosis dehiscence (n = 1), total parenteral nutrition (n = 4), and death (n = 1, PE).
The median follow-up time period was 19 months (range: 8–31 months). No patient experienced a recurrence of
pelvic disease.
Conclusions: Performing a central ligation of vessels supplying the tumor bed prior to an en bloc pelvic resection is
feasible with acceptable morbidity and mortality rates.
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Cytoreduction
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Background
Epithelial ovarian carcinoma (EOC) is the leading cause
of death due to gynecologic malignancy, and more than
60 % of women with newly diagnosed EOC present with
advanced stage disease [1]. Current standard treatment
for advanced ovarian cancer consists of a primary debulking
surgery (PDS) followed by platinum-based chemotherapy
[2, 3]. Several studies support a greater survival rate in pa-
tients who were optimally cytoreduced compared with pa-
tients who were suboptimally cytoreduced [4–7].
The possibility of excising all visible lesions (R = 0,
microscopic) is crucial for deciding whether to perform
an extensive cytoreductive surgery.
En bloc pelvic resection is effective for achieving ma-
ximal cytoreduction while eliminating the pelvic disease
in advanced primary EOC patients with extensive pelvic
organ involvement including viscera [8].
Lymphovascular ligation before tumor manipulation
during cancer resection is termed the “no-touch isola-
tion” technique [9]. This technique aims to reduce the
intraoperative dissemination of cancer cells and was pro-
posed by Barnes [10] to decrease the incidence of liver
metastases by diminishing the intraoperative dissemin-
ation of colorectal cancer cells.
Animal studies have confirmed this reduction [5], and
recent data in humans suggest a trend towards reduced
tumor cell dissemination with the no-touch isolation
method [11, 12]. The benefit of this method in terms of
improved patient survival, however, remains unproven [9].
To achieve cytoreduction to microscopic residual disease
in disseminated EOC cases with peritoneal and visceral
metastases consistent with the requirements of cancer no-
touch isolation, a modification of the en bloc pelvic resec-
tion procedure was introduced.
This modification aims initially to reach the retroperi-
toneal space where the lymphatic and vascular systems
supplying the cancer tissue are located. Next, a central
vascular ligation is performed. Finally, the intraperitoneal
cancer compartment (including the infiltrated portion of
bowel) is surrounded from the outside (healthy tissues) by
separating the involved peritoneum from the bladder and
the pelvic wall and then resected in one block. A colorec-
tal anastomosis is created.
This paper aims to present a new surgical approach




From May 2013 to October 2014, a modified en bloc
pelvic resection was performed on 20 patients with
advanced EOC at the Department of Gynecologic
Oncology, Oncology Center, in Red Cross Hospital in
Gdynia, Poland. The study was approved by the local
Ethics Committee (NKBBN/263/2012).
Inclusion criteria are as follows: age younger than 80 years
old, ASA performance status 0 to 2 [13], resectable disease
evaluated by computed tomography (CT) scan and/or
positron emission tomography (PET), no significant co-
morbidities, and provided informed written consent.
Exclusion criteria are as follows: other malignant patholo-
gies, an extra-abdominal metastasis, a complete intestinal
obstruction, or active infections.
The treatment plan consisted of performing a central
vascular ligation prior to an en block pelvic resection. This
treatment was a component of primary surgery aiming to
remove all visible disease using different types of perito-
nectomy with related resections defined by Sugarbaker
(Table 1) [14]. Each patient was operated on by JJS, who
designed the surgical plan. The observation period ended
1st October 2015.
Surgical plan
(1) Mobilization of the left and right colons
The peritoneum is incised along the lateral
peritoneal reflections immediately medial to
the white line of Toldt from the left and right
paracolic sulci cephalad to the splenic and
hepatic flexures of the colon. The mesentery
of the left and right colons is divided from its
retroperitoneal attachments (Fig. 1a).
Both ureters and the plane over Gerota’s fascia
are identified to avoid compromising the kidneys.
(2) Dissection and central ligation of ovarian vessels
The left and right ovarian vessels are dissected
and ligated at the level of the left renal vein and
the vena cava, respectively (Fig. 1b).
(3) Central lymphovascular ligation with retroperitoneal
selective lymph node dissection (if necessary)
The lymphovascular flow is ligated by several clips.
Enlarged, suspicious lymph nodes are excised at the
level of the left renal vein (LRV) down towards the
Table 1 The visceral resections and parietal peritonectomy
procedures
Type of peritonectomy Provided resections




Greater omentectomy and spleen
Right upper quadrant
peritonectomy




Old abdominal incisions, umbilicus,
and epigastric fat pad
Omental bursectomy Gallbladder and lesser omentum
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pelvis in one block. Where possible, a nerve-sparing
technique is used.
(4) Central vascular ligation of the tumor-bearing
segment of the colon
The inferior mesenteric artery (IMA) is ligated
on the aorta. The artery’s individual branches
are then resected as they arise from this vascular
trunk (Fig. 1b). The Y-configuration of the left
colic and sigmoidal vessels is converted to a
V-configuration to preserve the intermediate
arcade. The inferior mesenteric vein (IMV)
is divided as it courses around the duodenum.
(5) Division of the colon*
The colon is dissected 5 cm beyond the boundary of
the cancer. A previous central vascular ligation and
the mobilization of the left colon allowed for
packing all the viscera, including the proximal colon,
into the upper abdomen.
(6) Dissection of the mesorectum 2–3 cm below the
retroperitoneal flexure
(7) Stripping of the vesical peritoneum with the
underlying fatty tissues from the surface of the
bladder
The point of tissue transection is precisely located
between the bladder musculature and its adherent
fatty tissue with peritoneum. The inferior limit of
the dissection is the anterior wall of the vagina.
(8) Stripping of the parietal peritoneum
The peritoneal incision around the pelvis is
connected to the peritoneal incisions in the right
and left paracolic sulci. The parietal pelvic
peritoneum is transected from the muscles and
fascia down towards the intraperitoneal space. The
inferior limits of the dissection are marked by
the boundaries formed by the broad ligament
(the mesoovarium, the mesosalpinx, and the
mesometrum), the mesorectum, and the mesocolon.
(9) Extraperitoneal cutting of the broad ligament
The round ligaments are divided as they enter the
internal inguinal ring.
(10) Central ligation of the uterine arteries
Uterine arteries are ligated laterally to the ureter at
their origin, the anterior division of the internal iliac
artery (marginal ligation). This ligation enables the
excision of the entire parametrium in one block with
the main specimen.
(11) Dissection of the uterus at the level of the fornices
of the vagina
The lower aspect of the uterus is dissected from the
vagina, and the vaginal cuff is closed.
(12) Dissection of the rectum
The rectovaginal septum is exposed. The perirectal
fat is divided 2–3 cm beneath the peritoneal
reflection so that the portion of the tumor
occupying the cul-de-sac is removed intact with the
specimen. The rectal musculature is skeletonized
using electrosurgery so that a stapler/purse-string
can be used to close the rectal stump. Finally, the
rectum is divided, and the cancer specimen is
removed.
(13) Creation of a colorectal anastomosis
The proximal colon is anastomosed to the rectal
remnant with a stapling device.
End-to-end: A circular stapling device is passed into
the rectum, and the trochar penetrates the staple
line. A purse-string applier is used to secure the
Fig. 1 The crucial steps of the proposed modification. a Entry into the extraperitoneal space and mobilization of the left and right colons. b Central
vascular ligation of the tumor-bearing segment
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stapler anvil in the distal descending colon.
The body of the circular stapler and anvil are mated,
and the stapler is activated to complete the low
colorectal anastomosis.
Side-to-end: The purse-string clamp is applied at
the inferior level of the resection. A straight needle
is passed through the clamp to form purse-string
sutures, which are used to secure the staple anvil in
the rectal stump.
The lumen of the colon is visualized and
progressively widened using three dilators of
increasing diameters (25, 28, and 31 mm). The EEA
instrument is inserted through the end of the colon,
and the trochar penetrates the sidewall of the bowel.
The body of the circular stapler and anvil are mated,
and the stapler is activated. The circular stapler is
then removed, and the distal end of the colon is
closed below the colorectal anastomosis with a
linear stapler TA 55.
(14)Leak testing
Of colorectal anastomosis
To evaluate the stapled colorectal anastomosis, the prox-
imal and distal tissue rings are examined for completeness.
Air leak testing is conducted, and air is insufflated into
the rectum with a water-filled pelvis to check for an air-
tight circle of staples. Two hands should easily pass be-
neath the sigmoid colon to ensure no tension at the
stapled anastomosis. A rectal examination is conducted
to check for staple-line bleeding at the anastomosis.
Of the bladder
The integrity of the bladder is analyzed with an intraoper-
ative methylene-blue test (IMBT).
*The division of the colon is delayed, while a greater
omentectomy is conducted first. This order of opera-
tions enables an assessment of the “oncological cleanli-
ness” of the entire colon to select the optimal place for
cutting. The splenic flexure and the transverse colon are
frequently involved, which involvement is hidden by the
metastatic omentum.
Results
The median age of patients was 58 years (range: 36–
80 years). The median body mass index (BMI) was
25.7 (range: 21–30). High-grade serous ovarian cancer
(HGSOC) was the predominating histological type and
was detected in 15 of 20 (75 %) cases. The most common
FIGO stage was IIIC confirmed in 50 % of patients. Most
cases presented with ascites exceeding 1000 ml (80 %).
Detailed data of the pre-treatment and disease-related
characteristics are shown in Table 2.
In all cases, no gross residual disease was achieved. In
all cases, histopathology results also confirmed bowel
infiltration of the cancer cells with the involvement of
mesenteric lymph nodes in 11 cases (55 %). Operative
details are shown in Table 3. Samples of the removed
tumor bed and the oncological clearness of the pelvis
after surgery are shown in Fig. 2. The median duration
of the procedure and hospital stay was 320 min (range:
205–430 min) and 12 days (range: 7–44 days), respectively.
The median estimated blood loss (EBL) was 600 cm3
(range: 400–1000 cm3). Nineteen patients received blood
transfusions (99 %). The median number of red blood cell
(RBC) transfusion units was 4 (range: 0 to 6 units). Six of
20 patients (30 %) required postoperative intensive care.
The median number of days spent by these patients in the
intensive care unit (ICU) was 4 (range: 1–6 days). Four pa-
tients received total parenteral nutrition (20 %).
One patient experienced a complication associated
with en bloc resection, namely an anastomosis site leak.
This patient accordingly underwent further surgery during
the same admission. The anastomosis site leak was man-
aged with a diversion colostomy and pelvic cavity drain-
age. The colostomy was reversed after chemotherapy was
complete. There were no surgery-related deaths; however,
one woman died 12 days post-surgery. Her death was due
to pulmonary embolismus, though all 20 patients received
combined pharmacologic and mechanical methods of
Table 2 Patients characteristics
Feature Value/no. of patients
Median age years 58 years (range 36–80)



















aAmerican Society of Anesthesiologists Classification of Physical Status
bInternational Federation of Gynecology and Obstetrics
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prophylaxis of venous thromboembolism (VTE) during
hospital stay.
All surviving patients (n = 19) received platinum-based
chemotherapy. The median number of days between the
primary surgery and the first cycle of chemotherapy was
48 days (range: 20–147 days). The median follow-up
time period was 19 months (range: 8–31 months). No
patient experienced a recurrence of disease during the
time of observation. Detailed data on the course of treat-
ment for particular cases are shown in Table 4.
Discussion
The conventional technique procedure prioritizes the
mobilization of the tumor-bearing segment followed by
central vascular ligation and the ligation of other portions
of the vasculature. Conversely, the no-touch isolation
technique prioritizes central vascular ligation, followed by
the mobilization of the tumor-bearing segment [9].
In advanced EOC, multi-visceral and peritoneal metasta-
ses create a tumor-bearing segment supplied by the extra-
peritoneal vascular system.
It is well-known that a complete peritonectomy and
visceral resections are required to achieve a complete
clearance of pan pelvic disease in these patients. The
preponderance of data suggests that colon resection to
achieve optimal cytoreduction positively impacts sur-
vival rates [15].
To achieve cytoreduction of microscopic residual dis-
ease in disseminated EOC cases consistent with the re-
quirements of cancer no-touch isolation, a modified en
bloc pelvic resection was proposed. This modified resec-
tion aims to initially reach the retroperitoneal space
where the central vascular ligation is performed.
In the first step of the operation, the peritoneum is
incised along the lateral peritoneal reflections immedi-
ately medial to the white line of Toldt from the left and
right paracolic sulci cephalad to the splenic and hepatic
flexures of the colon. The mesentery of the left and
right colons is divided from all its retroperitoneal at-
tachments. This dividing not only enables the identifi-
cation of the ovarian and mesentery vessels but also
elevates the entire colon with metastatic omentum, thus
allowing the affliction of the upper abdomen with cancer
to be properly assessed.
Fig. 2 Intraperitoneal cancer compartment (including the infiltrated part of the bowel) and oncological clearness following the modified en block
pelvic resection
Table 3 The visceral resections and parietal peritonectomy
procedures conducted during primary debulking surgery (PDS)
Type of peritonectomy Provided resections No.
of patients























epigastric fat pad 0
Omental bursectomy Gallbladder and lesser
omentum
0
Type of lymhadenectomy Selective PALND/PLND 10
Systematic PALND/PLND 2
Sznurkowski World Journal of Surgical Oncology  (2016) 14:133 Page 5 of 8
It has been suggested that the inefficiency of upper ab-
domen surgery limits optimal cytoreduction [16]. Hence,
this surgical step could reveal all potentially unresectable
lesions and is therefore proposed to initiate all aggressive
surgical plans to eradicate EOC.
The left and right ovarian vessels are dissected and li-
gated at the level of the left renal vein and the vena cava,
respectively.
Central vascular ligation of the tumor-bearing segment
of the colon is performed. From a practical perspective,
this ligation should be proceeded by the opening of the
omental bursa to assess the “oncological cleanliness” of
the colon.
The surgical plan includes central lymphovascular li-
gation and retroperitoneal lymph node dissection (LND).
LND is a questionable procedure to use in cases of ad-
vanced ovarian cancer. We aimed to excise enlarged, sus-
picious nodes during the cytoreduction or to perform a
systematic lymphadenectomy in cases with cancer spread
macroscopically limited only to the pelvis. Current pro-
spective studies such as the LION study (AGO-Ovar) will
confirm the appropriateness of using LND in EOC. Not-
ably, none of the 12 cases showed postoperative lympho-
cele with the lymph node dissection, which result could
indicate another positive impact of performing the central
lymphovascular ligation prior to excising enlarged, suspi-
cious nodes.
The next proposed modification entails an excision of
the entire segment of affected peritoneum, including areas
without visible lesions. For example, if the peritoneal me-
tastases are present in the pelvis, a complete pelvic perito-
nectomy is conducted. Recently, radical surgery together
with hyperthermic intraperitoneal chemotherapy (HIPEC)
as described by Sugarbaker [14] has been widely promoted
for use in EOC cases.
Sugarbaker did not excise uninvolved surfaces of the
peritoneum because he believed that microscopic disease,
if unaddressed, will be eradicated by HIPEC performed
immediately after surgery. Existing evidence suggests that
primary debulking surgery followed by HIPEC has an un-
expectedly negative impact on prognosis in EOC [17]. The
results of ongoing randomized control trials will be
published not sooner than in the next 3 years. There-
fore, the approach of excising the entire segment of in-
volved peritoneum, rather than performing experimental
perioperative intraperitoneal chemotherapy, seems rea-
sonable, particularly given the lack of observed complica-
tions related to the excision in our cohort.
Rationale for modification
The impact of no tough isolation technique on intraope-
rative cancer dissemination will be difficult to prove.
However, the proposed central vascular ligation should,
if not decrease intraoperative cancer dissemination, at
Table 4 Modified en block pelvic resection—course of treatment
Age years Surgery duration minutes EBL cc ICU days RBC units PN Surgical complication Hospital stay days Time between PDS and Cht days
62 205 400 0 2 0 0 7 32
58 310 600 0 4 0 0 13 31
38 350 900 3 5 0 0 9 44
62 350 400 0 4 Anastomosis leak 25 48
36 280 700 0 4 0 0 7 51
74 210 400 0 0 0 0 12 62
80 270 1000 5 6 1 0 12 x death
65 380 650 5 4 1 Wound infection 44 147
64 345 400 5 1 1 0 12 52
64 310 600 0 4 1 0 18 48
52 305 450 0 1 0 0 13 48
55 410 400 0 2 0 0 9 35
66 320 550 0 3 0 0 15 61
54 300 700 0 5 0 0 11 53
55 430 950 1 5 0 0 12 26
72 320 400 0 2 0 0 12 31
48 345 600 0 4 0 0 9 56
59 300 800 0 6 0 0 12 60
46 355 500 0 3 0 0 8 20
54 345 700 1 4 0 0 20 25
EBL estimated blood loss, ICU intensive care unit, RBC red blood cell, PN parenteral nutrition, PDS primary debulking surgery, Cht chemiotherapy
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least decrease complications such as blood loss and lym-
phocoele formation. Elevating the entire colon while
opening the retroperitoneal space seems to be highly re-
liable for predicting optimal cytoreduction. Excising the
entire segment of involved peritoneum, including areas
without visible lesions, is safe and could be a cost-effective
alternative for HIPEC.
Course of treatment
The duration of surgery and hospitalization was com-
parable to the respective durations reported in other
studies on en block pelvic resection published after
2000 [18–24]. Patients in our cohort had a lower EBL
and the highest rate of complete cytoreduction com-
pared with other reports [18–24]. We believe that the
decrease in blood loss is caused by the introduction of
central vascular ligation and by the fact that surgery is
starting from the healthy tissues surrounding the tumor
compartment. It was proven that the tumor-bearing
segment has increased vascularization caused by cancer
neoangiogenesis [25]. A surgical operation conducted
through an anatomically unchanged (i.e., healthy) com-
partment could also be responsible for the increased re-
sectability of ovarian cancer tissue.
We observed anastomosis leakage in 1 of 20 cases
(5 %). Only in one recent study was the percentage of
this complication is higher (8.7 %) [23]. Remaining studies
published after 2000 show lower rates of anastomosis
leakage, namely 0.8 %, [19] 1.7 % [21], 2.2 % [22], 3 % [24],
3.2 % [20], and 4.5 % [18]. All studies on en block pelvic
resection were conducted with a limited number of cases,
and the subsequent results of the studies do not reflect
the real (average) rate of the anastomosis leakage of colo-
rectal anastomosis. A meta-analysis of randomized control
trials (RCTs) of colorectal anastomosis surgery published
in 2001 revealed that the overall stapled clinical leak rate
is 6.3 % [26]. Given these data, our results (5 %) seem fully
acceptable.
The single complication observed in our study could
be explained by the poor nutritional status of the pa-
tient. We routinely analyzed serum albumin levels prior
to surgery, yet this method appeared to be ineffective in
identifying patients with severe nutritional risk. Since
our study, we have incorporated an assessment of nutri-
tional status based on the European Society of Parenteral
Nutrition (ESPEN) Guidelines on Enteral Nutrition [27]
into our qualification process. Currently, all patients
with severe nutritional risk receive parenteral nutrition
for 10–14 days prior to surgery even if surgery must be
consequently delayed.
Recent studies on stapled colorectal anastomosis have
indicated side-to-end anastomosis as safer than end-to-end
anastomosis [28]. Side-to-end anastomosis tends to fill the
pelvis, reducing the area of dead space in which a
hematoma or collection of hematomas could develop [29].
Indeed, our observed case of leakage was one of two
cases in which end-to-end colorectal anastomosis was
created, which could thus be additional reason for the
complication.
There were no surgery-related deaths; however, one
woman died due to pulmonary embolismus 12 days
post-surgery. She received combined pharmacologic and
mechanical methods of prophylaxis of VTE during her
hospital stay. Post mortem, it was found that she had
been a mutation carrier of factor V Leiden. This fact was
unpredictable; thus, we believe that her death should not
affect the appraisal of the described surgical procedure.
All surviving patients received six courses of platinum-
based chemotherapy.
The time interval from surgery to the start of chemo-
therapy was 48 days (range: 20–147 days). This interval
is longer than the average period of 4–5 weeks reported
in the literature [30]. This delay has been suggested as
impairing a patient’s prognosis [31]. Recently, however,
it was demonstrated that the timing of postoperative
chemotherapy did not influence the overall survival rate
in women without postoperative residual disease [30].
Indeed, none of our optimally debulked patients experi-
enced a recurrence of the disease during the time of
our observation. The median follow-up occurred only
19 months following surgery (range: 8–31 months). PFS
periods reported in the literature range from 14 to
18 months [32]; hence, we believe that an en bloc pelvic
resection preceded by a central ligation of the vessels
supplying the tumor bed could potentially improve the
outcome of ovarian cancer patients.
Prospective clinical trials with a control group are needed
to assess the exact oncological benefit of the presented
approach.
Summary of proposed modification
The tumor-bearing segment (pelvis) is not touched. In
the first step, a retroperitoneal space is opened by incising
along the lateral peritoneal reflections immediately medial
to the white line of Toldt from the left and right paracolic
sulci cephalad to the splenic and hepatic flexures of the
colon. This method enables the vessels supplying tumor
bed to be reached and ligated first (ovarian and mesenteric
anterior vessels) as well as the lymph nodes involvement to
be assessed. In advanced cases (including omental cake),
this step should be proceeded by opening the omental
bursa to assess the “oncological cleanliness” of the colon.
Mobilization of the entire colon allows a proper determin-
ation of the affliction of the upper abdomen by cancer.
Finally, intraperitoneal cancer compartment (including
the infiltrated portion of the bowel) is surrounded from
the outside (healthy tissues) by separating the entire
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peritoneum (not merely the involved portion) from the
bladder and the pelvic wall and then resecting in one
block. A colorectal anastomosis is created. In our co-
hort of 20 ovarian cancer patients, this new approach
resulted in low blood loss and a high rate of optimal
cytoreduction.
Conclusions
Performing a central ligation of vessels supplying the
tumor bed prior to an en bloc pelvic resection is feasible
with acceptable morbidity and mortality rates. The im-
pact of this modification on intraoperative cancer spread
and the decrease in blood loss as well as oncological out-
come should be confirmed in future studies.
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